[Sending recorded video] Recombumin | Recombinant human albumin enabling safe and robust manufacturing across various modalities.

Registration for this webinar has closed. If you wish to view it, please contact us. We will send you the URL for the recorded video at a later date.
In biopharmaceutical manufacturing, productivity, consistency, and safety of processes are emphasized, but it is said that ensuring stability in cell gene therapy is particularly challenging. Recombumin, due to its diverse physicochemical properties, improves cell survival rates after freeze preservation and suppresses aggregation of cells and vectors, thereby enhancing process productivity. Its strengths include very small inter-batch variability, high safety due to the absence of animal-derived components, and a regulatory compliance system in place in Japan. In this webinar, we will welcome Mr. Kazushige Sugama, a technical advisor from Albumedix, as a guest speaker to introduce examples of pharmaceutical manufacturing utilizing Recombumin's properties, particularly in gene cell therapy.
【Seminar Overview】
▪ Date: March 7 (Thursday) from 3:00 PM (approximately 45 minutes)
▪ Format: Webinar recorded broadcast [Japanese, Free]
*We sincerely apologize, but participation from companies in the same industry and email addresses other than those of your organization is not permitted. Thank you for your understanding.

Date and time | Thursday, Mar 07, 2024 03:00 PM ~ |
---|---|
Entry fee | Free |
Inquiry about this news
Contact Us OnlineMore Details & Registration
Details & Registration